C2i Genomics
Whole-genome Cancer Treatment Intelligence Platform
Company Overview
Snapshot
Founded in August 2019 by Asaf Zviran, Boris Oklander, and Ezra Sofer, C2i Genomics operated with 11–50 employees. The company raised a total of $113.2M across 3 funding rounds from 9 investors. In January 2024, C2i Genomics was acquired by Veracyte.
Business overview
C2i Genomics developed a whole-genome cancer treatment intelligence platform, offering a SaaS solution that leverages a cloud-based platform for cancer tumor burden monitoring. The company's core technology combines whole genome sequencing with a proprietary AI-based tumor enrichment method to recognize patient-specific cancer patterns. This enables high-precision personalized medicine, aiming to reduce cancer treatment costs and accelerate drug development. C2i Genomics served the health tech and life sciences sector, focusing on digital medical diagnostics, and catered to healthcare providers, insurance companies, and pharmaceutical firms.
Strategic signal
In January 2024, C2i Genomics was acquired by Veracyte. This acquisition signals a strategic consolidation within the digital health and medical diagnostics sector, indicating a strong market interest in advanced genomic technologies for cancer detection and monitoring. For investors, this highlights the value placed on AI-powered platforms that can enhance personalized medicine and streamline cancer treatment.
Company Intelligence Q&A
- What was the most significant recent corporate event for C2i Genomics?
- This marks a significant exit for the company and integration into a larger entity in the diagnostics space.
- When was C2i Genomics founded and by whom?
- C2i Genomics was founded in August 2019 by Asaf Zviran, Boris Oklander, and Ezra Sofer.
- What was C2i Genomics' last funding round?
- C2i Genomics secured its last funding round in April 2021, a Series B round, with Casdin Capital participating as a lead investor.
- What strategic partnership did C2i Genomics form in early 2023?
- In January 2023, AstraZeneca announced plans to evaluate C2i Genomics' cancer detection and monitoring platform, indicating a significant collaboration with a major pharmaceutical company.